Comparison of trimethoprim sulfadiazine and doxycycline in the treatment of acute respiratory tract infections
Salmi, H.A.; Mattila, J.
Drugs under Experimental and Clinical Research 9(10): 725-730
The combination of trimethoprim and sulfadiazine (TMP-SD) was compared with doxycycline in the treatment of acute respiratory tract infections in a randomized, double-blind clinical trial. TMP-SD was given 160-500 mg twice daily and doxycycline 150 mg once daily for 7-10 days depending on the clinical condition. The patients were 100 conscripts hospitalized for acute respiratory infection warranting antibacterial treatment. The most frequent diagnoses were pneumonia and bronchitis; tonsillar infections were not included. The efficacy of the treatment was evaluated on the basis of the clinical response. All cases where another antibacterial drug was required were regarded as failures. The overall efficacy of the therapy was 88% (44 of 50 patients) in both treatment groups. There was no difference between the 2 treatments when individual diagnostic groups were compared. The occurrence of side-effects was 4% in both treatment groups.